NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...

Fruits and vegetables, as a type of food, are characterized by the presence of health-beneficial components, such as dietary ...